VTCN1 and neoplasm: The ABL103—a bispecific antibody that binds to B7H4 and 4-1BB (4-1BB is a highly potent costimulatory molecule expressed in T and NK cells)—simultaneously potently inhibited tumour progression in a dose-dependent manner and showed a higher rate of complete remission.